Efficacy, Tolerability and Safety of Azilect in Subjects With Progressive Supranuclear Palsy

Progressive Supranuclear Palsy Clinical Trial

— PROSPERA  

Official title:

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Rasagiline in Subjects With Progressive Supranuclear Palsy (Phase III)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01187888
• Other study ID #: 08P02
• Secondary ID: 2008-007520-26
• Status: Terminated
• Phase: Phase 3
• First received: August 20, 2010
• Last updated: April 23, 2013
• Start date: January 2010
• Est. completion date: June 2012

Study information

• Verified date: April 2013
• Source: Ludwig-Maximilians - University of Munich
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether rasagiline is effective in the treatment of Progressive Supranuclear Palsy (PSP), a rapidly progressing disease with a symptomatology similar to Parkinson's Disease. The major aim of this study is the limitation or halting of the process of neurodegeneration and influence postural instability.

Description:

Progressive Supranuclear Palsy (PSP) is a rapidly progressing disease with a median survival after onset of symptoms of 5.8 years.PSP is characterized by early falls, vertical ophthalmoparesis, akinetic-rigid features, prominent bulbar dysfunction and fronto-subcortical dementia. So far there is no treatment for the disease as the negative outcomes of the vast majority of studies make it impossible to set standards. As the majority of patients experience severe falls and vertigo already in the early phase of the disease, the drug of desire would be able to slow disease progression with a special focus on postural instability and exert neuroprotective effects. The monoamino oxidase inhibitor Rasagiline might be able to influence progression of PSP.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 44
• Est. completion date: June 2012
• Est. primary completion date: June 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 50 Years to 80 Years

Eligibility

Inclusion Criteria:

• Clinical signs of Progressive Supranuclear Palsy (PSP). Diagnosis will be made for patients with clinical probable PSP (Litvan et al., 1996). Patients will be included with PSP stage </= II (Golbe et al., 1997), at least with a PSPRS < 40 (Golbe et al., 2007) and according to the diagnostic criteria resumed after the Neuroprotection and Natural History in Parkinson Plus Syndromes (NNIPPS) trial (Bensimon et al., 2009)

• Patients, male or female, aged 50 to 80 years

• Subjects whose clinical condition at the time of enrolment does not or requires a low [</= 500 mg /day] stable dose of L-3,4-Dihydroxyphenylalanine (L-DOPA) for at least 2 weeks prior to study entry

• Capability and willingness to give written signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study

Exclusion Criteria:

• No clinically probable PSP

• No written informed consent possible

• Age > 80 or < 50 years

• Dementia (Mini-Mental State Examination [MMSE] </= 24)

• Subjects with clinically significant psychiatric illness, including major depression

• Subjects who have taken any experimental drugs within 60 days prior to baseline

• Subjects who have used sympathomimetics (including over-the-counter remedies - nasal or oral), dextromethorphan, pethidine or St. John's wort within 7 days prior to baseline.

• Loss of postural reflexes (no independent walking possible, inability to stand unassisted, wheelchair-bound)

• Feeding tube / recommendation for a feeding tube

• Unintelligible speech

• History of brain disease (e.g. repeated strokes, cerebral tumour, hydrocephalus)

• 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) exposure

• Oculogyric crisis

• Early severe autonomic failure

• Systemic disorder affecting the brain

• Women who are not postmenopausal (e.g. one year without menstrual periods) or surgically sterilized.

• Known history of hypersensitivity to the investigational drug or to drugs with a similar chemical structure

• Subjects who have used antidepressants, including selective serotonin re-uptake inhibitors, tricyclic and tetracyclic antidepressants (except amitriptyline <= 50 mg/day, trazodone < = 100 mg/day, citalopram < = 20 mg/ day, sertraline < = 100 mg/day and paroxetine < = 30 mg/day, escitalopram < = 10 mg/day) within 42 days prior to baseline

• Subjects who have used any drugs known to have been involved in a drug interaction via inhibition of hepatic Cytochrome P450 1A2 (CYP 1A2) within 30 days prior to baseline (cimetidine, ciprofloxacin, clarithromycin, enoxacin, erythromycin, fluvoxamine, isoniazide, nalidixic acid, norfloxacin, troleandomycin, zileuton)

• Subjects who have used Monoamine oxidase (MAO) inhibitors including reserpine and methyldopa within three months prior to baseline

• Anti-emetic or antipsychotic medication with central dopamine antagonist activity (except quetiapine fumarate) within six months prior to baseline

• Participation in a clinical trial within the last 30 days prior to study start

• Unstable antiparkinsonian medication within 30 days before baseline

• Previous use of Rasagiline or Selegiline

• Subjects who have a clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation (based on the investigator's judgment). Such conditions might include cardiovascular, vascular diseases, pulmonary, hepatic impairment (Child-Pugh score > 5), renal, or metabolic dis-eases or malignancies as determined by medical history, physical examination, laboratory tests, or ECG

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Progressive Supranuclear Palsy
• Supranuclear Palsy, Progressive

Intervention

Drug:
• Rasagiline
tablet once daily 1 mg 1 year
• Sugar pill
tablet once daily one year

Locations

Country	Name	City	State
Germany	Department of Neurology and Palliative Care Klinikum der Universität München (Hospital of the University of Munich)	München

Sponsors (3)

Lead Sponsor	Collaborator
Prof. Dr. Stefan Lorenzl	Ludwig-Maximilians - University of Munich, Teva Pharmaceutical Industries

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the need for additional L-DOPA therapy or the need to increase the dose of L-DOPA during the trial	Since there is no established treatment regimen for Progressive Supranuclear Palsy (PSP) patients, the only well characterized medication is L-3,4-Dihydroxyphenylalanine (L-DOPA) therapy. Since this therapy may exert a small effect in PSP patients, begin with L-DOPA therapy or increase in L-DOPA therapy will be used in this trial as rescue medication.	1 year	No
Primary	Reduction of the reported deterioration using the PSP rating scale	To assess the efficacy of Rasagiline using the Progressive Supranuclear Palsy Rating Scale (PSPRS), aiming at a 33% reduction of the reported deterioration (Golbe et. al., 2007), i.e. a mean yearly increase of 6.5 instead of 9.7 points.	1 year	No
Secondary	Reduction of gait disturbances and postural stability		1 year	No
Secondary	Adverse Event (AE) incidence		1 year	Yes
Secondary	Safety laboratory values (blood cell count, aspartate aminotransferase [AST], alanine aminotransferase [ALT], creatinine, Vitamin B12, folic acid, homocysteine and methylmalonic acid)		1 year	Yes
Secondary	Vital signs		1 year	Yes
Secondary	Number of subjects (%) who discontinue the study		1 year	No
Secondary	Number of subjects (%) who discontinue the study due to AEs		1 year	No